Area 1255
New member
So I got my hands on the 12-hour long acting beta-agonist inhaler thingy known as formoterol..which in some studies has been shown to decrease myostatin and have a stronger anabolic effect than both clenbuterol and albuterol. It comes with pierceable capsules that you load into an inhaler, but the best way I've found is to inhale one 12mcg capsule , and orally take a half of another - 6 mcg in some water or hold it under your tongue, but don't put the capsule in your mouth, it's hard to break down. just open it up and hold the powder under neath your tongue.
Formoterol treatment downregulates the myostatin ... [Oncol Lett. 2012] - PubMed - NCBI
http://aups.org.au/Proceedings/43/41P/41P.pdf
Neuromuscul Disord. 2007 Jan;17(1):47-55. Epub 2006 Nov 28.
Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Harcourt LJ1, Schertzer JD, Ryall JG, Lynch GS.
Author information
Abstract
The beta(2)-adrenoceptor agonist (beta(2)-agonist), formoterol, has been shown to cause muscle hypertrophy in rats even when administered at the micromolar dose of 25 micro g/kg/day. We investigated whether a similar low dose of formoterol could improve muscle function in the dystrophic mdx mouse. Ten-week-old male mdx and wild-type (C57BL/10) mice were administered formoterol (25 micro g/kg/day, i.p.) for 4 weeks. Formoterol treatment increased extensor digitorum longus (EDL) and soleus muscle mass, increased median muscle fibre size in diaphragm, EDL, and soleus muscles, and increased maximum force producing capacity in skeletal muscles of both wild-type and mdx mice. In contrast to other studies where beta(2)-agonists have been administered to mice and rats, generally at higher doses, low dose formoterol treatment did not increase the fatiguability of EDL, soleus or diaphragm muscles. Although others have found formoterol can decrease ubiquitin mRNA and proteasome activity when administered to tumour bearing rats at high doses (2mg/kg/day), in the present study low dose formoterol treatment did not alter ubiquitin or the E1 and E3 ubiquitin ligases in diaphragm muscles of wild-type or mdx mice, but it did reduce the level of ubiquitinated proteins in diaphragm of wild-type mice. The findings indicate that formoterol has considerably more powerful anabolic effects on skeletal muscle than older generation beta(2)-agonists (like clenbuterol and albuterol), and has considerable therapeutic potential for muscular dystrophies and other neuromuscular disorders where muscle wasting is indicated.
Now I know some they have been skeptical, but I think this report will help lay out everything quite nicely.
Things I noticed so far...
I've been using it straight for a week.
I can see some serious cutting benefits and some mass gain down the road.
Formoterol treatment downregulates the myostatin ... [Oncol Lett. 2012] - PubMed - NCBI
Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.
Busquets S1, Toledo M, Marmonti E, Orpí M, Capdevila E, Betancourt A, López-Soriano FJ, Argilés JM.
Author information
Abstract
Cachexia is a common systemic manifestation. Additionally, myostatin is known to be a negative regulator of skeletal muscle development. The present study aimed to investigate whether formoterol down-regulates the myostatin system in skeletal muscle of tumour-bearing rats. Real-time PCR and Western blotting were used for the analysis. Results showed that rats bearing the Yoshida AH-130 ascites hepatoma, a cachexia-inducing tumour, exhibited marked muscle wasting that affected the mass of the muscles studied. The cachectic animals exhibited a significant increase in the mRNA levels of the myostatin receptor (ActIIB) in gastrocnemius muscles. Notably, the expression of the various forms of follistatin, a protein with the opposite effects to those of myostatin, was significantly reduced as a result of the implantation of the tumour. When the animals were treated with formoterol, a β-agonist with anti-cachectic potential, increases in skeletal muscle weights were observed. The β-agonist significantly increased levels of various follistatin isoforms and significantly decreased the expression levels of the myostatin receptor. In addition, formoterol treatment resulted in a significant decrease of the myostatin protein content of the gastrocnemius muscle. In conclusion, the results presented indicate that certain anabolic actions of formoterol on the skeletal muscle of cachectic animals may be mediated via the myostatin system.
http://aups.org.au/Proceedings/43/41P/41P.pdf
Neuromuscul Disord. 2007 Jan;17(1):47-55. Epub 2006 Nov 28.
Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Harcourt LJ1, Schertzer JD, Ryall JG, Lynch GS.
Author information
Abstract
The beta(2)-adrenoceptor agonist (beta(2)-agonist), formoterol, has been shown to cause muscle hypertrophy in rats even when administered at the micromolar dose of 25 micro g/kg/day. We investigated whether a similar low dose of formoterol could improve muscle function in the dystrophic mdx mouse. Ten-week-old male mdx and wild-type (C57BL/10) mice were administered formoterol (25 micro g/kg/day, i.p.) for 4 weeks. Formoterol treatment increased extensor digitorum longus (EDL) and soleus muscle mass, increased median muscle fibre size in diaphragm, EDL, and soleus muscles, and increased maximum force producing capacity in skeletal muscles of both wild-type and mdx mice. In contrast to other studies where beta(2)-agonists have been administered to mice and rats, generally at higher doses, low dose formoterol treatment did not increase the fatiguability of EDL, soleus or diaphragm muscles. Although others have found formoterol can decrease ubiquitin mRNA and proteasome activity when administered to tumour bearing rats at high doses (2mg/kg/day), in the present study low dose formoterol treatment did not alter ubiquitin or the E1 and E3 ubiquitin ligases in diaphragm muscles of wild-type or mdx mice, but it did reduce the level of ubiquitinated proteins in diaphragm of wild-type mice. The findings indicate that formoterol has considerably more powerful anabolic effects on skeletal muscle than older generation beta(2)-agonists (like clenbuterol and albuterol), and has considerable therapeutic potential for muscular dystrophies and other neuromuscular disorders where muscle wasting is indicated.
Now I know some they have been skeptical, but I think this report will help lay out everything quite nicely.
Things I noticed so far...
I've been using it straight for a week.
- Only need to dose once a morning by the way , 12 hour effect is clean, with a little OCD anxiety....go on.
- Absolutely ridiculous and unprovoked motivation to work out, it internalizes the energy to such an extent that you just have to work out.
- Eliminates almost all soreness it seems, recovery times are definitely shortened.
- Crazy endorphin rush, usually I add in yohimbine with albuterol, but with form there is no need for either, but I do stack it with caffeine.
- Seems to be increasing my strength quite a bit. The amount of reps on the bench and with calisthenics is greater on each set.
- Very impressed so far... will continue logging.
I can see some serious cutting benefits and some mass gain down the road.